BioNTech’s Bold Leap: Navigating Financial Tides and Pioneering New Frontiers in Cancer Research
BioNTech faces a challenging 2024 with declining pandemic-related revenues and profits, marking a significant financial shift. The company's earnings dropped to €1.08 per share, below market expectations, and revenues fell…